About: Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 2004

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2004 (uk) im Februar 2004 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 2004 (ast) artikull shkencor i botuar më 01 shkurt 2004 (sq) scientific article published on 01 February 2004 (en)
publication date	wds:Q76383446-E7335DD0-15E4-46F5-AC2F-0AC4A9355FB3
publication date	2004-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q76383446-7D48E8AF-BA2C-4544-B68F-B942B9A6207C
language of work or name	English
author name string	wds:Q76383446-133ECB19-4FEC-40AA-A67E-B2CCECE572DC wds:Q76383446-1B0F5364-038E-4273-9BED-C6026A82369E wds:Q76383446-799243F1-9259-40FD-9CD7-83A01C7B5BD6 wds:Q76383446-AE3232BE-0DAA-4094-8740-5A46A0A605D2 wds:Q76383446-EDDD345E-412B-4B86-BCFD-6A5CC4109AFE
author name string	Philip Rhodes Robert Steffen Weigong Zhou Thomas Linder Christian Spyr
rdfs:label	Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (en) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (nl) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (sq)
skos:prefLabel	Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (en) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (nl) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (sq)
name	Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (en) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (nl) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (sq)
author	wds:Q76383446-01DA7EA6-7D40-4EDA-BB04-8326A58C692F wds:Q76383446-3CF77109-055F-452A-AFEC-C70452996FFB wds:Q76383446-E4DD30D8-B22C-4986-A136-F7B255478CD7
author	Matthias Bopp Robert T. Chen Margot Mütsch
title	wds:Q76383446-ABEF0BF8-6336-4839-B739-5B91577CA7E6
title	Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland (en)
page(s)	wds:Q76383446-F1BAE510-4F62-441E-980D-1208E9EC6970
page(s)	896-903
instance of	wds:Q76383446-7C92116B-B66B-43FF-BD92-1BEDA77F8354
instance of	scholarly article
main subject	wds:Q76383446-0CE8C502-6570-49B3-AEE9-3DD1E679FE9B wds:Q76383446-5787FA6E-6084-403B-AEC0-D477538842DD wds:Q76383446-8C5D19E2-C976-487F-8213-C2FBB19B86B2 wds:Q76383446-DEFCD02C-0644-4E27-8CF3-3238D2975977
main subject	Bell's palsy vaccine Switzerland influenza vaccine
PubMed ID	wds:Q76383446-DB879506-26DE-4A67-B65F-B859D3EAFE9C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14985487
PubMed ID	14985487
published in	wds:Q76383446-3DF48906-5F1F-47F9-8C84-46FD0F50B224
published in	The New England Journal of Medicine
issue	wds:Q76383446-F93723C3-C0B8-4FCF-AF28-B58C4F42BBF3
volume	wds:Q76383446-CB71FFB5-C619-4CC1-8F4D-80A22D2C913F
issue	9
volume	350
DOI	wds:Q76383446-64D8524A-1C9D-4234-851D-BDFD58D446AA
DOI	http://dx.doi.org/10.1056/NEJMOA030595
DOI	10.1056/NEJMOA030595
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q76383446
is cites work of	Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity Issues in the design and implementation of vaccine trials in less developed countries Studies on the usefulness of intranasal inactivated influenza vaccines Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs NALT- versus Peyer's-patch-mediated mucosal immunity Induction of secretory immunity and memory at mucosal surfaces Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens Vaccines for preventing influenza in healthy adults Vaccines for preventing influenza in healthy adults The state of the science of health care epidemiology, infection control, and patient safety, 2004. CpG oligodeoxynucleotides as mucosal adjuvants The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid The next decade of vaccines: societal and scientific challenges Local immune responses following nasal delivery of an adjuvanted influenza vaccine Mucosal vaccines: the promise and the challenge Vaccines for preventing influenza in healthy adults Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. Recent progress in mucosal vaccine development: potential and limitations Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice Sublingual vaccination with influenza virus protects mice against lethal viral infection Sublingual immunization induces broad-based systemic and mucosal immune responses in mice Influenza vaccines: a moving interdisciplinary field. Enhancing oral vaccine potency by targeting intestinal M cells The mucosal immune system for vaccine development Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software